Antisense inhibition of protein kinase C-theta expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsC. Frank Bennett, Lex M. Cowsert
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of Protein kinase C-theta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein kinase C-theta. Methods of using these compounds for modulation of Protein kinase C-theta expression and for treatment of diseases associated with expression of Protein kinase C-theta are provided.
Claims14
An antisense compound 8 to 30 nucleobases in length targeted to nucleotides 35 to 55 of a 3′-untranslated region, nucleotides 76 to 117 of a start codon, nucleotides 139 to 2214 of a coding region, nucleotides 2196 to 2224 of a region which overlaps at least one nucleotide of a stop codon or nucleotides 2223 to 2743 of a 5′-untranslated region of a nucleic acid molecule encoding human Protein kinase C-theta, wherein said antisense compound specifically hybridizes with and inhibits the expression of human Protein kinase C-theta.
Dependencies are inferred from the claim text.